SPOTLIGHT: Investors expected to boost GSK, AZ

Credit Suisse lifted its share-price targets for GlaxoSmithKline, AstraZeneca, and Shire, saying it expects the pharma sector to be something of a port in a storm for investors worried about the economy. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.